Faruqi and Faruqui, LLP Logo
Share this page

Ocular Therapeutix, Inc. (OCUL)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ:OCUL) of the September 5, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Ocular stock or options between May 5, 2017 and July 6, 2017 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Ocular securities between May 5, 2017 and July 6, 2017 (the “Class Period”).  The case, Gallagher v. Ocular Therapeutix, Inc. et al, No. 2:17-cv-05011 was filed on July 7, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Ocular’s management has been misleading investors about the Company’s lead product, DEXTENZA, manufacturing issues, including that more than 50% of lots manufactured by Ocular contain bad product; (2) these manufacturing issues could imperil the approval of DEXTENZA by the U.S. Food and Drug Administration (“FDA”); and (3) as a result, the Company’s public statements were materially false and misleading.

Specifically, on July 6, 2017, an article released on Seeking Alpha claimed, in part, that the Company “has been misleading investors about manufacturing,” including that more than 50% of lots manufactured by the Company contain bad product. Then later on July 6, 2017, STAT published an article claiming that DEXTENZA could be rejected by the FDA because of product contamination found by an FDA inspector during a visit to the Company’s manufacturing facility.

On this news, Ocular’s share price fell from $9.50 per share on July 6, 2017 to a closing price of $7.12 on July 7, 2017—a $2.38 or a 25.05% drop.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Ocular Therapeutix, Inc. (OCUL)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 07/07/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.